Claims
- 1. A non-enterically coated dosage form comprising:
a) a proton pump inhibitor; b) a buffer; and c) a non-steroidal anti-inflammatory drug.
- 2. The dosage form of claim 1 wherein the buffer is selected from the group consisting of a water soluble buffer, a water insoluble buffer, and a combination of a water soluble buffer and a water insoluble buffer.
- 3. The dosage form of claim 1 wherein the non-steroidal anti-inflammatory drug is aspirin.
- 4. The dosage form of claim 3 wherein the proton pump inhibitor is lansoprazole.
- 5. The dosage form of claim 4 wherein the dosage form comprises aspirin at an amount between 50 mg and 100 mg.
- 6. A method of treating a condition selected from the group consisting of angina, aorto-pulmonary shunt occlusion, colorectal cancer, esophageal cancer, colon cancer, coronary artery disease, dementia, dysmenorrhea, myocardial infarction, rheumatoid arthritis, osteoarthritis, pain, headache, migraine headache, stroke, thrombocythemia, post-operative thrombeoembolism, ischemia, bursitis, cognative decline, fever, gout, musculoskelatal disorders, soft tissue injury, and pericarditis; wherein the method comprises administering to a patient having one or more of the above conditions a non-enterically coated dosage form comprising a buffer, a proton pump inhibitor, and a non-steroidal anti-inflammatory drug.
- 7. A method of protecting the gastrointestinal tract from NSAID therapy comprising administering a NSAID in combination with a buffer and a PPI wherein the NSAID, PPI and buffer comprise a single non-enterically coated dosage form.
Parent Case Info
[0001] This application claims priority to U.S. Provisional Application Serial No. 60/434,967, filed Dec. 20, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60434967 |
Dec 2002 |
US |